Preclinical data demonstrate Xevudy (sotrovimab) retains activity against key Omicron mutations, new SARS-CoV-2 variant. GlaxoSmithKline

These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021..

See-"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2".;Andrea L Cathcart, Colin Havenar-Daughton, Florian A Lempp, et al. doi: https://doi.org/10.1101/2021.03.09.434607.